Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY:XLV)

130.67 -0.91 (-0.69%)
Streaming Delayed Price Updated: 12:13 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
S&P 500 2022 Q4 Earnings Review: Swing And A Miss
In many ways, this quarter behaved in a way that met the expectations of most market commentators, earnings are too high, an erosion of pricing power since the pandemic, and that higher costs will bite... 
Via Talk Markets
Identifying The Dimension Where Deterministic Chaos Is Alive In The Stock Market
We have estimated approximate entropy for the S&P 500 and its SPDR ETF and we have noticed that all of them have non-linear dependence patterns for the dimension of 3 or 4 days. 
Via Talk Markets
Tuesday Talk: My Sweet CPI
The street is hoping for sweet January CPI data today and that anticipation pushed stocks higher on Monday. 
Via Talk Markets
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
A Bull Market Is Coming. Should You Return to Growth Stocks?
Growth stocks could be among the first to rally in a bull market. 
Via The Motley Fool
Budding Sign Not To Miss
Encouraging signs from corporate junk bonds, stocks are likely to get a tailwind to open 2023. 
Via Talk Markets
This Low-Risk ETF Can Turn $39,000 Into $1 Million in 25 Years
Funneling money into this fund can drastically simplify your investing strategy. 
Via The Motley Fool
10 Names For Half The Move
In January, sectors like Tech, Communication Services, and Consumer Discretionary saw massive outperformance following the opposite playing out throughout 2022. 
Via Talk Markets
Sector Divergence, Earnings Stats
Over these last few weeks, as the broad market has rallied, we've definitely seen some sector divergence. 
Via Talk Markets
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%. 
Via Talk Markets
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength. 
Via Talk Markets
Rotating Regimes – What To Plan For In 2023
Throughout the second half of 2022, active managers turned to sector rotation to help mitigate and recover from substantial losses incurred already. Rotation into and out of low and high volatility... 
Via Talk Markets
Markets At Key Turning Point With Major Earnings Ahead
We saw initial selling in the market today and will be watching this particular key price level very closely this week and beyond. 
Via Talk Markets
Top Sector For 2023
Technical analysis and opinion on each sector in the stock market and which ones are likely to do the best, and which ones are most likely to lag the overall market. 
Via Talk Markets
Best ETFs, Funds, and Stocks of 2022. A Preview to 2023.
In 2022, high inflation and rising bond yields emerged as headwinds for stocks. The S&P 500 declined by over 18%, marking its worst yearly showing since 2008. 
Via Talk Markets
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
Small-cap speculative biotech stocks regain interest with volatility. 
Via Talk Markets
Market Awaits The CPI And Financial Earnings - Be Ready!
A look at the upcoming big events this week, which stocks are leading the rally with double-digit gains so far in 2023 and which smaller number of stocks started the year weak. 
Via Talk Markets
Biden, Trump, DeSantis: Cramer Says Concerns Over Next President Mean We May Be In For 'Second Leg' Of 'Vicious Rotation' Out Of Healthcare
The Health Care Select Sector SPDR Fund (NYSE: XLV) ended 2022 with a modest loss of 2.08%, a relative outperformance vis-a-vis the broader S&P 500 Index, 
Via Benzinga
Worried About 2023? Here's a Safer Way to Invest in Stocks This Year
By holding a broad range of stocks and spreading out your investment over the year, you can minimize your overall risk. 
Via The Motley Fool
Leading And Lagging Sectors For January 3, 2023
Gainers Symbol Name Price Change ($) Change (%) Volume 
Via Benzinga
Investing In 2023 - The Crucial Events Driving The Markets
Business decisions drive the business cycle. These decisions will impact the markets in 2023 and beyond. 
Via Talk Markets
The Year In Review And Ahead
We‘ll continue witnessing cost-push inflation combined with tight labor market – and it would be crude oil‘s time again to gain in value from current levels. 
Via Talk Markets
2022 Review: US Equity Sectors
Annual returns for equity sectors are always a study in contrasts, but the blowout performance of energy stocks in 2022 is unusually divergent vs. the rest of the field. 
Via Talk Markets
AI Stock Forecast: Fighting The Irrational Crowd By Investing Through AI
Deviation from rational thinking creates direct losses or opportunity costs in investing activity. AI can capture our biases and feelings, and uncover the knowledge that is covered for a general... 
Via Talk Markets
Has The Final Leg Of The Bear Market Begun?
The S&P 500 experienced a momentum reversal this week. What can we learn from history and a wide variety of charts and data sets? 
Via Talk Markets
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets. 
Via Talk Markets
A Stalwart Delivers
Since August, volatility has risen for all S&P 500 sectors, with Consumer Discretionary and Energy maintaining their status as the most volatile sectors. 
Via Talk Markets
Leading And Lagging Sectors For November 18, 2022
Gainers Symbol Name Price Change ($) Change (%) Volume 
Via Benzinga
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
The (Alarm) Bells Are Ringing For Me And My Gal
It is entirely reasonable with persistent inflation at current levels for S&P 500 earnings to come down to levels far lower than currently projected. 
Via Talk Markets
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.